Key Takeaways OGN unveils Phase 3 ADORING sub-analysis showing VTAMA improved sleep outcomes in pediatric AD patients.Data showed POEM sleep scores improved by week 1 in some cohorts, with benefits through week 8.Results support its strategy to target impactful dermatology outcomes after FDA approval in AD.Organon & Co. (OGN) recently announced findings from a pooled sub-analysis of its Phase 3 ADORING 1 and ADORING 2 pivotal trials assessing VTAMA (tapinarof) cream, 1%, in pediatric patients with moderate ...